Trans-aTTom: To offer more?

Regarder maintenant Trans-aTTom: To offer more?

Neoadjuvant vs adjuvant approaches in early TNBC

Regarder maintenant Neoadjuvant vs adjuvant approaches in early TNBC

Canadian Perspective on Overall survival (OS) in KATE2.

Regarder maintenant Canadian Perspective on Overall survival (OS) in KATE2.

KEYNOTE-119: Phase 3 study of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer.

Regarder maintenant KEYNOTE-119: Phase 3 study of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer.

Message from our Editor-in-Chief

Regarder maintenant Message from our Editor-in-Chief